In order to accelerate the development of antibacterial drugs, Cipla Therapeutics, an affiliate of Cipla Limited, entered into a strategic partnership SIGA Technologies, Inc. The partnership will deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.
- SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market.
- SIGA brings expertise in developing and improving US-based supply chains to enable robust delivery of medical countermeasures to the U.S. Government
The prominent deals and investments by Cipla are mentioned below:
Aug 2020: The Drug Controller General of India (DCGI) had approved the Stempeucel Cell Therapy by Cipla Limited and its partner Stempeutics Research Pvt. Ltd. The approval will help in the treatment of CLI due to Buergers Disease and Atherosclerotic Peripheral Arterial Disease.
May 2020: Cipla Limited had signed a non-exclusive licensing agreement with California based Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which had been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients.
February 2020: Cipla announced the acquisition of nutrition products portfolio from Wanbury Ltd. Cipla had acquired 4 brands CPink, CDense, Productiv and Folinine to further strengthen its presence in womens health.
January 2020: Cipla Foundation, the social responsibility arm of Cipla Ltd, had announced to set-up a world class chemistry research laboratory at the Indian Institute of Science Education and Research (IISER) Pune, in India.
About Cipla Ltd
Cipla, headquartered in Mumbai, India, is a leading pharmaceutical and biotechnology company. the company has presence in more than 80 countries and providing around 1,500 products across various therapeutic categories in approximately 50 dosage forms. The company has approximately 25,000 employees across the world.